PA8661701A1 - Tiazolidinonas, su preparacion y su uso como medicamento - Google Patents

Tiazolidinonas, su preparacion y su uso como medicamento

Info

Publication number
PA8661701A1
PA8661701A1 PA20068661701A PA8661701A PA8661701A1 PA 8661701 A1 PA8661701 A1 PA 8661701A1 PA 20068661701 A PA20068661701 A PA 20068661701A PA 8661701 A PA8661701 A PA 8661701A PA 8661701 A1 PA8661701 A1 PA 8661701A1
Authority
PA
Panama
Prior art keywords
thiazolidinones
preparation
medicinal product
kines
plk
Prior art date
Application number
PA20068661701A
Other languages
English (en)
Inventor
Knut Eis
Damian O Arnaiz
Volker Schulze
Dirk Kosemund
Olaf Prien
Gerhard Siemeister
Holger Hess-Stumpp
Uwe Eberspaecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PA8661701A1 publication Critical patent/PA8661701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE RELACIONA CON TIAZOLIDINONAS DE LA FORMULA GENERAL (I) SU PREPARACION Y SU USO COMO INHIBIDOR DE LA QUINAS POLO LIKE (PLK), PARA EL TRATAMIENTO DE DISTINTAS ENFERMEDADES.
PA20068661701A 2005-02-03 2006-02-03 Tiazolidinonas, su preparacion y su uso como medicamento PA8661701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005005395A DE102005005395A1 (de) 2005-02-03 2005-02-03 Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US65123205P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
PA8661701A1 true PA8661701A1 (es) 2006-12-07

Family

ID=36709709

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20068661701A PA8661701A1 (es) 2005-02-03 2006-02-03 Tiazolidinonas, su preparacion y su uso como medicamento

Country Status (18)

Country Link
US (1) US7511059B2 (es)
EP (1) EP1844027A1 (es)
JP (1) JP2008529985A (es)
CN (1) CN101155791A (es)
AR (1) AR052370A1 (es)
AU (1) AU2006210153A1 (es)
BR (1) BRPI0606140A2 (es)
CA (1) CA2596967A1 (es)
DE (1) DE102005005395A1 (es)
DO (1) DOP2006000024A (es)
GT (1) GT200600039A (es)
MX (1) MX2007009387A (es)
PA (1) PA8661701A1 (es)
PE (1) PE20061085A1 (es)
TW (1) TW200639155A (es)
UY (1) UY29358A1 (es)
WO (1) WO2006082107A1 (es)
ZA (1) ZA200707520B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004135533A (ru) * 2002-05-03 2005-07-20 Шеринг Акциенгезельшафт (De) Тиазолидиноны и их применение в качестве ингибиторов polo- подобной киназы
WO2007089862A2 (en) * 2006-01-31 2007-08-09 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
WO2009103010A2 (en) * 2008-02-13 2009-08-20 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
AU2009310805B2 (en) * 2008-10-29 2017-02-02 Fujifilm Corporation Dye, photoelectric conversion element using the same, photoelectrochemical cell, and method of producing dye
JP5629752B2 (ja) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
CN102892766B (zh) 2010-04-06 2015-05-20 大学健康网络 激酶抑制剂和用其治疗癌症的方法
CA2803446C (en) 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
LT3057965T (lt) * 2013-10-18 2019-03-12 University Health Network Plk-4 inhibitoriaus druska ir jos kristalinės formos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004135533A (ru) * 2002-05-03 2005-07-20 Шеринг Акциенгезельшафт (De) Тиазолидиноны и их применение в качестве ингибиторов polo- подобной киназы
JPWO2004043936A1 (ja) 2002-11-14 2006-03-09 協和醗酵工業株式会社 Ｐｌｋ阻害剤
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
BRPI0519040A2 (pt) * 2004-12-15 2009-01-13 Bayer Schering Pharma Ag tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos
DE102005020104A1 (de) * 2005-04-25 2006-10-26 Schering Ag Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents

Also Published As

Publication number Publication date
EP1844027A1 (de) 2007-10-17
ZA200707520B (en) 2008-11-26
DE102005005395A1 (de) 2006-08-10
TW200639155A (en) 2006-11-16
CA2596967A1 (en) 2006-08-10
US7511059B2 (en) 2009-03-31
WO2006082107A1 (de) 2006-08-10
CN101155791A (zh) 2008-04-02
AU2006210153A1 (en) 2006-08-10
JP2008529985A (ja) 2008-08-07
BRPI0606140A2 (pt) 2009-06-02
MX2007009387A (es) 2007-08-16
GT200600039A (es) 2006-09-06
DOP2006000024A (es) 2006-08-15
PE20061085A1 (es) 2006-11-11
US20060223833A1 (en) 2006-10-05
UY29358A1 (es) 2006-07-31
AR052370A1 (es) 2007-03-14

Similar Documents

Publication Publication Date Title
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
UY29264A1 (es) Tiazolidinonas metasustituidas, su preparación y su uso como medicamento
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
ECSP066717A (es) Compuestos de quinolina sustituidos
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
ECSP10010735A (es) Compuestos químicos 251
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
UY31484A1 (es) Piperidinas heteroaril-sustituidas
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
UY29876A1 (es) Derivados de acidos dicarboxilicos y su uso
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
PA8657701A1 (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
UY27733A1 (es) Derivados de ciclopenteno.
ATE435868T1 (de) Homogemcitabine
CR9323A (es) TIAZOLIDINONAS COMO INHIBIDORAS DE LAS POLOQUINASAS (Plk) COMO MEDICAMENTO
PA8666801A1 (es) Derivado de 5h-bensociclohepteno, procedimiento para su preparacion y su uso como antiinflamatorios
DOP2005000256A (es) Tiazolidinonas metasustituidas, su preparacion y su uso como medicamento